Clinical Science to Landmark Trials: TCT Satellite Event on November 4 at 6:30 a.m. EDT. Save the Date

AMI Cardiogenic Shock

Clinical Evidence

Key Findings from the National Cardiogenic Shock Initiative Study ^1,2,3

Identify and support cardiogenic shock early
Aggressive down titration of inotropes
Identify inadequate left ventricular (LV) support and escalate, if CPO <0.6
Identify right ventricular (RV) dysfunction early and support
Systematically use right heart catheter (RHC) to guide therapy

Graphic displaying the pathway to class 1 recommendation of Impella use in cardiogenic shock

Impella® Clinical Evidence Pathway to Class I Recommendation

Impella clinical evidence has established safety and effectiveness and validated best practices.

Graphic of clinical evidence supporting improved AMI cardiogenic shock outcomes when unloading pre-PCI

Ongoing and Upcoming Clinical Trials

RECOVER IV Randomized Controlled Trial

Upcoming trial to assess whether Impella pre-PCI is superior to PCI without Impella in patients with AMI cardiogenic shock.

NCSI Study

Ongoing trial seeking to improve mortality in patients with AMI cardiogenic shock using the NCSI algorithm.

DanGer Shock Randomized Controlled Trial

Ongoing trial assessing primary outcome of death from all causes at six months with Impella CP® compared to standard of care.

The Procedure

Learn more about femoral access explant techniques and other best practices.

References

Tehrani, B.N., et al. (2019). JACC, 73, 1659-1669.
Basir, M.B., et al. (2019). Catheter Cardiovasc Interv, 93(7), 1173-1183.
O’Neill, W.W., (2020). TCT Connect 2020

NPS-1187